立贝韦塔单抗（HH-003）获得美国FDA的 “突破性药物认定”

FDA granted Breakthrough Therapy Designation to Huahui Health's Libevitug (HH-003) for treating chronic hepatitis delta virus (HDV) infection.

在美国主流药物数据库可以查到：  https://www.hepb.org/research-and-programs/hepdeltaconnect/drug-watch/#:~:text=Phase%20II%20(planned%20enrollment%20starting,Huahui%20Health